

## Efficacy and safety of GLP-1 agonist therapy in overweight and obese subjects with cystic fibrosis-related diabetes: a pilot study

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

1. diagnosis of cystic fibrosis 2. diabetic using insulin 3. BMI 26 kg/m<sup>2</sup> or greater 4. able to read & speak English

---

**Exclusion Criteria:**

1. personal or family history of medullary thyroid cancer 2. chronic GI problems requiring hospitalization in the past year 3. history of suicide attempts or active ideas of suicide

### Conditions & Interventions

**Interventions:**

Drug: Semaglutide

**Conditions:**

Rare Diseases, Breathing, Lung & Sleep Health

**Keywords:**

Cystic Fibrosis, Clinics and Surgery Center (CSC)

### More Information

**Description:** In this study we will be looking at the safety and effectiveness of the medication GLP-1 (Semaglutide) in patients who are overweight and have been diagnosed with Cystic Fibrosis Related Diabetes (CFRD).

**Study Contact:** Catherine Larson - [sund0033@umn.edu](mailto:sund0033@umn.edu)

**Principal Investigator:** Amir Moheet

**IRB**

**Number:** STUDY00018575

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.